|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 39/395 | (2006.01) |
| A61K 39/395 | (2013.01) | ||
| A61K 31/519 | (2006.01) | ||
| A61K 39/39558 | (2013.01) | ||
| A61K 31/4162 | (2006.01) | ||
| A61K 31/519 | (2013.01) | ||
| A61P 35/00 | (2006.01) | ||
| C07K 16/2887 | (2013.01) | ||
| C07K 16/28 | (2006.01) | ||
| A61P 35/00 | (2018.01) |
| (11) | Number of the document | 3500299 |
| (13) | Kind of document | T |
| (96) | European patent application number | 17841107.0 |
| Date of filing the European patent application | 2017-08-18 | |
| (97) | Date of publication of the European application | 2019-06-26 |
| (45) | Date of publication and mention of the grant of the patent | 2023-12-13 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/CN2017/098023 |
| Date | 2017-08-18 |
| (87) | Number | WO 2018/033135 |
| Date | 2018-02-22 |
| (30) | Number | Date | Country code |
| PCT/CN2016/096082 | 2016-08-19 | WO |
| (72) |
HU, Nan , CN
WANG, Lai , CN
SONG, Jing , CN
ZHANG, Tong , CN
LI, Kang , CN
LUO, Lusong , CN
WEI, Min , CN
WANG, Zhiwei , CN
GUO, Yunhang , CN
|
| (73) |
Beigene Switzerland GmbH ,
Aeschengraben 27, 4051 Basel,
CH
|
| (54) | COMBINATION OF ZANUBRUTINIB WITH AN ANTI-CD20 OR AN ANTI-PD-1 ANTIBODY FOR USE IN TREATING CANCER |
| COMBINATION OF ZANUBRUTINIB WITH AN ANTI-CD20 OR AN ANTI-PD-1 ANTIBODY FOR USE IN TREATING CANCER |